Gt biopharma announces gtb-3550 trike™ monotherapy rescues and restores nk cell immune surveillance in relapsed/refractory aml and mds cancer patients

Beverly hills, calif., april 12, 2021 /prnewswire/ -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary nk cell engager (trike™) protein biologic technology platform, announced today additional interim results from its gtb-3550 trike™ first-in-human phase i/ii clinical trial for the treatment of high-risk myelodysplastic syndromes (mds) and refractory/relapsed acute myeloid leukemia (aml).
GTBP Ratings Summary
GTBP Quant Ranking